Form: 10-Q

Quarterly report [Sections 13 or 15(d)]

November 13, 2026

Exhibit 32.1

Statement Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

By

Principal Executive Officer

Regarding Facts and Circumstances Relating to Exchange Act Filings

I, Jerel Banks, Chief Executive Officer of Benitec Biopharma Inc., hereby certify, to my knowledge, that:

1. the accompanying Quarterly Report on Form 10-Q of Benitec Biopharma Inc. for the three month period ended September 30, 2026 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Benitec Biopharma Inc.

IN WITNESS WHEREOF, the undersigned has executed this Statement as of the date hereof.

 

 

Date: November 13, 2026

By:

/s/ Dr. Jerel A. Banks

Dr. Jerel A. Banks

Chairman of the Board and Chief Executive Officer (principal executive officer)